Global Dermatology Market to 2022 - Uptake of Recently

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Dermatology Market to 2022 - Uptake of Recently Approved Premium Biologics will Drive the $33 Billion Market

Dublin, June 01, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth" report to their offering. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022.

Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline. This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. Scope The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products.

Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape. - Which molecular targets are most prominent within the pipeline? - How do the key indications differ in terms of molecule type? - How does the composition of the pipeline compare with that of the existing market? - What mechanisms of action are most common for pipeline drugs?

Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022. - Which products will contribute to market growth most significantly, and which will achieve blockbuster status? - Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change? - What CAGR will these companies register in the forecast period? Key Topics Covered: 1 Tables & Figures

2 Introduction 2.1 Therapy Area Introduction 2.2 Symptoms 2.3 Etiology and Pathophysiology 2.4 Co-morbidities and Complications 2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 2.6 Treatment

3 Key Marketed Products 3.1 Overview 3.2 Humira (adalimumab) 3.3 Remicade (infliximab) 3.4 Enbrel (etanercept) 3.5 Stelara (ustekinumab) 3.6 Neoral (cyclosporine) 3.7 Protopic (tacrolimus) 3.8 Elidel (pimecrolimus) 3.9 Elocon (mometasone furoate) 3.10 Differin (adapalene) 3.11 Metolate (methotrexate) 3.12 Clobex (clobetasol propionate) 3.13 Conclusion

4 Pipeline Landscape Assessment 4.1 Overview 4.2 Molecule Types in the Pipeline 4.3 Molecular Targets in the Pipeline 4.4 Clinical Trials 5 Multi-Scenario Market Forecast to 2022 5.1 Overall Market Size 5.2 Generic Penetration 5.3 Revenue Forecast by Molecular Target

6 Company Analysis and Positioning 6.1 Company Landscape 6.2 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations 7.1 Licensing Deals 7.2 Co-development Deals

8 Appendix

For more information visit http://www.researchandmarkets.com/research/4sxtrd/global

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into GoHealth, Inc. Sparks Investor Concerns

Updated Category News Views 354

GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...

Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla

Updated Category News Views 334

Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...

Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success

Updated Category News Views 65

Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...

Continue Reading
Green IT Services Growth: A Comprehensive Market Overview

Updated Category News Views 193

Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...

Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath

Updated Category News Views 558

Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...

Continue Reading